Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
UF-KURE-BCMA CAR-T Cells in Relapsed or Refractory Multiple Myeloma
NCT06698744Phase 1Withdrawn
- Start
- Sep 2025
- Primary completion
- Dec 2026
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of UF-KURE-BCMA CAR T-cells in multiple myeloma (MM). Primary endpoints: Recommended Phase 2 Dose at 28 days and Dose Limiting Toxicity at 28 days. Planned start Sep 2025; status: withdrawn.
02
Drugs
UF-KURE-BCMA CAR T-cells
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT06698744.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06698744.